This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity

NCT06536023 · Completed

Last updated 2026-05-28

This clinical trial tests the safety and how the body processes the drug IBI362 in Chinese teenagers who are obese.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 36 people

Who can join Ages 12–18 · all sexes

Timeline Started 2024-08 · est. completion 2025-08

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06536023 ↗

Description as written by the study sponsor.

The study is a first-in-pediatric assessment of the safety, tolerability, and pharmacokinetic characteristics of multiple doses of IBI362 in Chinese adolescent subjects with obesity. It employs a multicenter, randomized, double-blind, and placebo-controlled trial design. The study plans to enroll 36 adolescents (aged ≥12 years and \<18 years) with obesity who have experienced less than a 5% decrease in Body Mass Index (BMI) after at least 12 weeks of diet and exercise control.

Treatments tested

IBI362 Drug

IBI362 SA.QW
IBI362 placebo Drug

IBI362 placebo SA.QW

Main thing measured	Incidence of adverse events and serious adverse events
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions studied	Adolescents With Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06536023 ↗